Suppr超能文献

[糖皮质激素在支气管哮喘患者哮喘持续状态治疗方案中的应用]

[Glucocorticosteroids in the therapeutic program of status asthmaticus in patients with bronchial asthma].

作者信息

Petrov D

出版信息

Vutr Boles. 1989;28(1):86-90.

PMID:2741446
Abstract

The therapeutic efficacy of glucocorticosteroids in asthmatic state was studied in 216 asthmatic patients, 17 to 72 years of age (mean age 46.3 years). 141 patients (65.78%) were in the first stage, 57 patients were in the second stage and 18 patients were in the third stage of asthmatic state. The comparative assessment of the results shows that the glucocorticosteroids in high doses are obligatory in the treatment of asthmatic state independently of its stage. The initial dose is 1000-1200 mg of hydrocortisone and up to the 6-th hour a dose of 3000-3500 mg is reached. If the asthmatic state persists the total dose may reach 4000-7000 mg for 34-48 hours. When the asthmatic state is improved the dose is reduced with 25-50%. The use of high doses of glucocorticosteroids improves the outcome of asthmatic state.

摘要

在216名年龄在17至72岁(平均年龄46.3岁)的哮喘患者中研究了糖皮质激素在哮喘状态下的治疗效果。141名患者(65.78%)处于哮喘状态的第一阶段,57名患者处于第二阶段,18名患者处于第三阶段。结果的比较评估表明,无论哮喘状态处于何阶段,高剂量的糖皮质激素都是治疗哮喘状态所必需的。初始剂量为1000 - 1200毫克氢化可的松,到第6小时剂量可达3000 - 3500毫克。如果哮喘状态持续,在34 - 48小时内总剂量可能达到4000 - 7000毫克。当哮喘状态改善时,剂量减少25 - 50%。使用高剂量的糖皮质激素可改善哮喘状态的治疗结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验